diethylnitrosamine has been researched along with sorafenib in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carr, BI; Cavallini, A; D'Alessandro, R; Refolo, MG; Wang, M; Wang, Z | 1 |
| Allemeersch, J; Carmeliet, P; Casteleyn, C; Colle, I; Coulon, S; Geerts, A; Heindryckx, F; Libbrecht, L; Stassen, JM; Terrie, E; Van Vlierberghe, H | 1 |
| Chan, C; Felsher, DW; Gamrekelashvili, J; Greten, TF; Hewitt, S; Kapanadze, T; Kapoor, V; Korangy, F; Ma, C; Manns, MP; Zender, L; Zhao, F | 1 |
| Barbeiro, DF; Bida, PM; Carrilho, FJ; Coelho, AM; Cogliati, B; D'Albuquerque, LA; Kubrusly, MS; Mazo, DF; Oliveira, CP; Pereira, IV; Souza, HP; Stefano, JT; Torres, MM; Xerfan, MP | 1 |
| Elsadek, B; Kratz, F; Mansour, A; Saleem, T; Warnecke, A | 1 |
| Baglioni, M; Baron Toaldo, M; Bolondi, L; Cescon, M; Giovannini, C; Gramantieri, L | 1 |
| Abdelghany, RH; El-Ahwany, E; Goda, R; Helal, NS; Mahmoud, AAA; Saber, S | 1 |
| Ghanim, AMH; Saber, S; Younis, NS | 1 |
| Abd-Elbaset, M; Abo-Youssef, AM; Ahmed, OM; Mansour, AM | 1 |
| Chang, CC; Chen, Y; Chou, MC; Dinh, TK; Huang, JK; Huang, KW; Jan, JJ; Ke, YY; Lee, CJ; Shia, KS; Shiue, TY; Song, JS; Sung, YC; Ta, YN; Wu, CH; Yeh, KC; Yeh, TK | 1 |
10 other study(ies) available for diethylnitrosamine and sorafenib
| Article | Year |
|---|---|
c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyclic AMP-Dependent Protein Kinases; Diethylnitrosamine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Liver Neoplasms, Experimental; MAP Kinase Kinase Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins c-raf; Pyridines; Rats; Rats, Inbred F344; Signal Transduction; Sorafenib; Vitamin K 1 | 2011 |
The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine-induced mouse model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Diethylnitrosamine; Disease Models, Animal; Drug Therapy, Combination; Liver Neoplasms; Mice; Mice, Knockout; Mice, Transgenic; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Placenta Growth Factor; Pregnancy Proteins; Sorafenib; Treatment Outcome | 2013 |
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Diethylnitrosamine; Disease Models, Animal; Granulocyte-Macrophage Colony-Stimulating Factor; Heterografts; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Myeloid Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-myc; Sorafenib | 2013 |
Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model.
Topics: Animals; Chaperonin 60; Diet, High-Fat; Diethylnitrosamine; Disease Models, Animal; Fibrillar Collagens; Glutathione Transferase; HSP90 Heat-Shock Proteins; Interleukin-10; Interleukin-6; Liver Cirrhosis; Matrix Metalloproteinase 9; Mitochondria, Liver; Niacinamide; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phenylurea Compounds; Polarography; Protein Kinase Inhibitors; Rats, Sprague-Dawley; RNA, Messenger; Sorafenib; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Transcription Factors | 2015 |
The antitumor activity of a lactosaminated albumin conjugate of doxorubicin in a chemically induced hepatocellular carcinoma rat model compared to sorafenib.
Topics: Animals; Antibiotics, Antineoplastic; Biomarkers, Tumor; Carcinoma, Hepatocellular; Diethylnitrosamine; Doxorubicin; Humans; Kaplan-Meier Estimate; Liver; Liver Neoplasms, Experimental; Male; Niacinamide; Phenylurea Compounds; Rats; Rats, Wistar; Serum Albumin; Sorafenib; Survival Rate | 2017 |
Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Proliferation; Cytokines; Diethylnitrosamine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Hepatocytes; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Rats, Wistar; Scorpions; Signal Transduction; Sorafenib; Spider Venoms; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cyclin D1; Diethylnitrosamine; Fosinopril; Liver Neoplasms, Experimental; Losartan; Male; Matrix Metalloproteinase 2; Mice; NF-kappa B; NF-KappaB Inhibitor alpha; Niacinamide; Perindopril; Phenylurea Compounds; Phosphorylation; Renin-Angiotensin System; Signal Transduction; Sorafenib; Time Factors; Transcription Factor RelA; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2018 |
Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cyclin D1; Diethylnitrosamine; Hep G2 Cells; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Liver Neoplasms; Male; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Mebendazole; Mice; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Signal Transduction; Sorafenib; Tissue Inhibitor of Metalloproteinase-1; Tumor Burden; Vascular Endothelial Growth Factor A | 2019 |
The potential chemotherapeutic effect of β-ionone and/or sorafenib against hepatocellular carcinoma via its antioxidant effect, PPAR-γ, FOXO-1, Ki-67, Bax, and Bcl-2 signaling pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Proliferation; Diethylnitrosamine; Ki-67 Antigen; Liver Neoplasms; Male; Nerve Tissue Proteins; Norisoprenoids; Oxidative Stress; PPAR gamma; Proto-Oncogene Proteins c-bcl-2; Rats, Wistar; Signal Transduction; Sorafenib | 2020 |
A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Diethylnitrosamine; Drug Synergism; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Lymphocytes, Tumor-Infiltrating; Male; Mice; Molecular Docking Simulation; Rats; Receptors, CXCR4; Signal Transduction; Sorafenib; T-Lymphocytes, Cytotoxic; Tumor Microenvironment; Tumor-Associated Macrophages; Xenograft Model Antitumor Assays | 2021 |